• mAbxience will hold the marketing authorization for the biosimilar candidate in Croatia and Slovenia, while Corapharm will assume this role across Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania.

• This partnership combines mAbxience’s expertise in biosimilar development with Corapharm’s strong presence and commercial capabilities in these markets, aiming to improve patient access to advanced and affordable treatments.

Madrid, Spain, June 2^nd, 2025 — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Corapharm are pleased to announce a new strategic licensing agreement to develop and commercialize a biosimilar candidate in Southeast Europe.

Under the terms of the agreement, mAbxience will hold the marketing authorization for the biosimilar candidate in Croatia and Slovenia, while Corapharm will assume this role across Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania. Corapharm will lead commercialization efforts throughout these territories, with mAbxience overseeing the product’s development and manufacturing at its state-of-the-art facilities.

“We are excited to partner with Corapharm to bring this biosimilar candidate to patients across Southeast Europe. Our collaboration reflects mAbxience’s commitment to delivering high-quality, accessible therapies across various geographies,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.

“Building on our successful track record in the pharmaceutical industry, we look forward to working with mAbxience to improve patient outcomes and expand access to critical treatments in these countries,” noted Mr. Miroslav Roca, CEO of Corapharm d.o.o.. “Together, we remain dedicated to enhancing patient care and addressing the rising costs of biologic therapies.”

This agreement marks another milestone in mAbxience’s strategy to provide affordable, life-saving therapies worldwide. Both mAbxience and Corapharm expect that this partnership will enhance patient access to advanced treatments, while also helping healthcare systems manage the rising costs of biologic therapies.